Lexibulin

Drug Profile

Lexibulin

Alternative Names: CYT 997

Latest Information Update: 25 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytopia Limited
  • Developer YM BioSciences Australia
  • Class Antineoplastics; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glioblastoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 08 Feb 2013 YM BioSciences has been acquired by Gilead Sciences
  • 07 Nov 2010 Discontinued - Phase-II for Multiple myeloma in Australia (IV)
  • 01 Feb 2010 Cytopia Limited has been acquired by YM BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top